Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) in a research note issued to investors on Sunday. The brokerage set a "buy" rating on the biotechnology company's stock.

A number of other research analysts also recently weighed in on ADAP. Wells Fargo & Company reduced their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research report on Friday, March 21st. Guggenheim reduced their price objective on Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a report on Wednesday, March 26th. HC Wainwright lowered their target price on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, Scotiabank cut their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research note on Friday, March 21st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $1.83.

Adaptimmune Therapeutics Stock Performance

Adaptimmune Therapeutics stock traded down $0.02 during mid-day trading on Friday, reaching $0.22. 605,061 shares of the company's stock were exchanged, compared to its average volume of 1,781,708. The business's fifty day simple moving average is $0.43 and its 200 day simple moving average is $0.61. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a one year low of $0.20 and a one year high of $1.48. The firm has a market capitalization of $55.30 million, a PE ratio of -0.98 and a beta of 2.84.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). The business had revenue of $3.22 million for the quarter, compared to the consensus estimate of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. On average, sell-side analysts expect that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several institutional investors have recently made changes to their positions in ADAP. Two Sigma Investments LP grew its position in shares of Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 19,146 shares in the last quarter. Virtu Financial LLC boosted its holdings in Adaptimmune Therapeutics by 21.5% in the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 21,688 shares during the period. Invesco Ltd. grew its position in shares of Adaptimmune Therapeutics by 82.0% during the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 28,526 shares in the last quarter. FMR LLC increased its holdings in shares of Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock worth $1,655,000 after purchasing an additional 50,419 shares during the period. Finally, Rock Springs Capital Management LP raised its position in shares of Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock worth $1,338,000 after buying an additional 58,000 shares in the last quarter. Hedge funds and other institutional investors own 31.37% of the company's stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.